BPC-157 is expected to return to legal compounding in 2026. Join the waitlist for first access the day it does.
BPC-157 is currently classified as FDA Category 2 and cannot be legally compounded for routine patient use. We will notify you the moment this changes and we are able to offer it.
BPC-157 is a 15-amino acid peptide originally isolated from human gastric juice. In preclinical research, it has demonstrated the ability to promote angiogenesis, stimulate fibroblast proliferation, reduce pro-inflammatory cytokines, and support tendon-to-bone integration.
That last mechanism is what caught my attention as an orthopedic surgeon. Tendon-to-bone integration is one of the hardest problems in musculoskeletal medicine — it's the reason rotator cuff repairs fail. BPC-157's mechanism is exactly what we would design if we could engineer a repair peptide from scratch.
We are waiting for legal clearance. When it comes, we will move immediately.
We'll notify you the moment BPC-157 becomes available.